Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ex-Takeda exec Tadataka Yamada rejoins Frazier Healthcare

This article was originally published in Scrip

Executive Summary

Frazier Healthcare, a provider of growth capital to healthcare companies, has announced Dr Tadataka Yamada will rejoin the firm. He will serve as a venture partner on the life sciences team, focused on creating new companies as well as providing strategic guidance to existing portfolio companies. He will also be a senior advisor to the growth buyout team, where he will provide advice on opportunities in pharmaceutical services and spin-outs from large healthcare companies, and sit on boards of portfolio companies such as PCI, a large pharmaceutical services company in the Frazier portfolio. Before rejoining Frazier, Dr Yamada was chief medical and scientific officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the company's board of directors. Previously he was chair of R&D at GlaxoSmithKline and a member of the company's board. 

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts